Use of Multiple Sources of Electronic Healthcare Record (EHR) Drug Data to Study Somatostatin Analogue (SSA) Dosing for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Treatment

被引：0
|
作者：
Jalbert, Jessica J. [1 ]
Meng, Jie [2 ]
Brais, Lauren K. [3 ]
Dutton, Trevor [3 ]
Pulgar, Sonia J. [4 ]
Berthon, Anthony [5 ]
Gabriel, Sylvie [5 ]
Dinet, Jerome [5 ]
Kulke, Matthew H. [3 ]
Casciano, Roman [1 ]
机构：
[1] LASER Analyt, New York, NY USA
[2] LASER Analyt, Lorrach, Germany
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[5] Ipsen Pharma SAS, Boulogne, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2017年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
198
引用
收藏
页码：122 / 122
页数：1
相关论文
共 10 条
  • [1] Somatostatin analogs (SSA) treatment in G1-G2 gastroenteropancreatic neuroendocrine tumors (GEP-NET): A single centre experience
    Marconcini, R.
    Ricci, S.
    Galli, L.
    Antonuzzo, A.
    Derosa, L.
    Farnesi, A.
    Biasco, E.
    Vasile, E.
    Caponi, S.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S633 - S633
  • [2] Expression of Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Neoplasm and Multicenter Retrospective Clinical Study of Octreotide LAR in the Treatment of Advanced GEP-NET
    Yuhong, W.
    Wei, W.
    Kaizhou, J.
    Cheng, F.
    Zhiwei, Z.
    Chenghao, S.
    Minhu, C.
    Xianjun, Y.
    Jie, C.
    NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [3] First Clinical Study of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET): Patient Dosimetry Assessment with the Somatostatin Receptor Antagonist 68Ga-OPS202
    Beykan, S.
    Nicolas, G. P.
    Fani, M.
    Mena, R.
    Kaufmann, J.
    Bouterfa, H.
    Bejot, R.
    Wild, D.
    Lassmann, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S89 - S90
  • [4] Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
    Berthon, A.
    Bjorstad, A.
    Granfeldt, D.
    Marlow, T.
    Dinet, J.
    Myrenfors, P.
    Lesen, E.
    Bjorholt, I
    Elf, A. K.
    Johanson, V
    NEUROENDOCRINOLOGY, 2018, 106 : 134 - 134
  • [5] Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
    Berthon, A.
    Granfeldt, D.
    Bjorstad, A.
    Marlow, T.
    Dinet, J.
    Myrenfors, P.
    Lesen, E.
    Bjorholt, I
    Elf, A. K.
    Johanson, V
    NEUROENDOCRINOLOGY, 2018, 106 : 61 - 61
  • [6] Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
    Halperin, Daniel M.
    Morris, Michael
    Ulaner, Gary A.
    Strosberg, Jonathan R.
    Mehr, Samuel H.
    Li, Daneng
    Soares, Heloisa P.
    Anthony, Lowell Brian
    Kotiah, Sandy Diana
    Jacene, Heather
    Tesselaar, Margot E. T.
    Kunz, Pamela L.
    Ferreira, Denis Vasconcelos
    Li, Joanne
    Ma, Kimberly
    Rearden, Jessica
    Moran, Susan
    Hope, Thomas A.
    Singh, Simron
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings
    Morris, Michael
    Ulaner, Gary
    Halperin, Daniel M.
    Strosberg, Jonathan
    Mehr, Sam
    Li, Daneng
    Soares, Heloisa
    Anthony, Lowell
    Kotiah, Sandy
    Jacene, Heather
    Pavel, Marianne
    Kunz, Pamela
    Ferreira, Denis
    Li, Joanne
    Ma, Kimberly
    Rearden, Jessica
    Moran, Susan
    Singh, Simron
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [8] ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis
    Morris, Michael
    Ulaner, Gary A.
    Halperin, Daniel M.
    Strosberg, Jonathan R.
    Mehr, Samuel H.
    Li, Daneng
    Soares, Heloisa P.
    Anthony, Lowell Brian
    Kotiah, Sandy Diana
    Jacene, Heather
    Pavel, Marianne E.
    Kunz, Pamela L.
    Ferreira, Denis Vasconcelos
    Li, Joanne
    Ma, Kimberly
    Rearden, Jessica
    Moran, Susan
    Hope, Thomas A.
    Singh, Simron
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.
    Strosberg, Jonathan R.
    Morris, Michael
    Ulaner, Gary A.
    Halperin, Daniel M.
    Mehr, Samuel H.
    Li, Daneng
    Soares, Heloisa P.
    Anthony, Lowell Brian
    Kotiah, Sandy Diana
    Jacene, Heather
    Tesselaar, Margot E. T.
    Kunz, Pamela L.
    Ferreira, Denis Vasconcelos
    Li, Joanne
    Ma, Kimberly
    Rearden, Jessica
    Moran, Susan
    Hope, Thomas A.
    Singh, Simron
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [10] Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Valle, Juan W.
    Bohas, Catherine Lombard
    Maisonobe, Pascal
    Atlan, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
1